NMTR 9 Meters Biopharma | 5/25/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | |
ONCT Oncternal Therapeutics | 4/3/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | |
NMTR 9 Meters Biopharma | 3/22/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
APGN Apexigen | 3/10/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | |
ONCT Oncternal Therapeutics | 3/9/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
DARE Daré Bioscience | 2/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
|
FUSN Fusion Pharmaceuticals | 2/13/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
HEPA Hepion Pharmaceuticals | 1/31/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
BCEL Atreca | 1/20/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
ECOR electroCore | 1/12/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | |
APGN Apexigen | 12/12/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
IMNN Imunon | 11/14/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
NMTR 9 Meters Biopharma | 10/25/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
VXRT Vaxart | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
OTLK Outlook Therapeutics | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
NMTR 9 Meters Biopharma | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
MNPR Monopar Therapeutics | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
LSTA Lisata Therapeutics | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
IMNN Imunon | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
EDSA Edesa Biotech | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
ATE Antibe Therapeutics | 8/15/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | |
ARCT Arcturus Therapeutics | 8/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
BCEL Atreca | 8/8/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
ATBPF Antibe Therapeutics | 6/30/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | |
VERU Veru | 5/18/2022 | Target Raised by | Brookline Capital Management | Analyst Kumaraguru Raja | Buy -> Buy | $29.00 -> $31.00 | Medium | |
VRCA Verrica Pharmaceuticals | 3/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | |
NTLA Intellia Therapeutics | 3/7/2022 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Hold -> Buy | $91.00 | High | |
CTIC CTI BioPharma | 3/1/2022 | Target Raised by | Brookline Capital Management | Analyst L. Cann | Buy -> Buy | $7.20 -> $12.00 | High | |
CRSP CRISPR Therapeutics | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | $143.00 | High | |
NTLA Intellia Therapeutics | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | | Low | |
CRBU Caribou Biosciences | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | |
BCDA BioCardia | 2/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
FUSN Fusion Pharmaceuticals | 2/2/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | |
ICCM IceCure Medical | 2/1/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | |
HEPA Hepion Pharmaceuticals | 1/26/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
DARE Daré Bioscience | 1/19/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
PROC Procaps Group | 12/14/2021 | Reiterated by | Brookline Capital Management | Analyst Kemp Dolliver | Buy | $13.00 | Low | |
PNT POINT Biopharma Global | 12/1/2021 | Reiterated by | Brookline Capital Management | Analyst Kemp Dolliver | Buy | $23.00 | Medium | |
CTIC CTI BioPharma | 11/15/2021 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | High | |
NOVN Novan | 10/19/2021 | Reiterated by | Brookline Capital Management | Analyst Kemp Dolliver | Buy | $16.00 | Medium | |
|
KYMR Kymera Therapeutics | 10/13/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | $80.00 | Medium | |
FBRX Forte Biosciences | 9/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Hold | | Low | |
VERU Veru | 8/27/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | |
SCYX SCYNEXIS | 8/24/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
BCEL Atreca | 7/29/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
CCCC C4 Therapeutics | 6/25/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | | High | |
ATE Antibe Therapeutics | 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | |
ATBPF Antibe Therapeutics | 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | |
MNPR Monopar Therapeutics | 5/25/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | |
BIOX Bioceres Crop Solutions | 5/7/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | |
SQZ SQZ Biotechnologies | 3/30/2021 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | N/A | |
ONCT Oncternal Therapeutics | 3/30/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | $16.00 | High | |
NMTR 9 Meters Biopharma | 3/25/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
MRNA Moderna | 2/26/2021 | Target Raised by | Brookline Capital Management | | Buy | $180.00 -> $205.00 | Low | |
XFOR X4 Pharmaceuticals | 12/17/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $21.00 | High | |
VERU Veru | 12/14/2020 | Target Raised by | Brookline Capital Management | Analyst K. Raja | | $13.00 -> $17.00 | High | |
SYRS Syros Pharmaceuticals | 11/10/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $190.00 | Low | |
CTIC CTI BioPharma | 10/23/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $7.00 | Medium | |
ECOR electroCore | 10/23/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $75.00 | Low | |
AWH Aspira Women's Health | 10/14/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | |
AWH Aspira Women's Health | 10/14/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | |
MEIP MEI Pharma | 10/12/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | |
DMTK DermTech | 9/11/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | |
MDNA Medicenna Therapeutics | 8/24/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | |
FBRX Forte Biosciences | 8/28/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $90.00 | Low | |
HUGE FSD Pharma | 8/20/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
HUGE FSD Pharma | 8/20/2020 | Initiated by | Brookline Capital Management | | Buy | $11.00 | N/A | |
KURA Kura Oncology | 8/16/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Low | |
NMTR 9 Meters Biopharma | 8/18/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $100.00 | High | |
VERU Veru | 8/14/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
ARCT Arcturus Therapeutics | 8/11/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
ATE Antibe Therapeutics | 7/15/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | |
MRNA Moderna | 7/13/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | $95.00 | High | |
ASRT Assertio | 6/3/2020 | Initiated by | Brookline Capital Management | | Buy | $3.50 | Low | |
OTLK Outlook Therapeutics | 5/5/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
DARE Daré Bioscience | 4/28/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $7.50 | High | |
EDSA Edesa Biotech | 3/30/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $10.00 | High | |
CLPT ClearPoint Neuro | 3/11/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | |
ARMP Armata Pharmaceuticals | 3/13/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
CLPT ClearPoint Neuro | 3/12/2020 | Initiated by | Brookline Capital Management | | Buy | $15.00 | N/A | |
MNPR Monopar Therapeutics | 2/19/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $42.00 | High | |
BIOX Bioceres Crop Solutions | 2/4/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | |
BCDA BioCardia | 11/26/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
BCDA BioCardia | 11/26/2019 | Initiated by | Brookline Capital Management | | Buy | $22.00 | Low | |
MDNA Medicenna Therapeutics | 11/19/2019 | Reiterated by | Brookline Capital Management | | Buy | C$4.00 | N/A | |
BCEL Atreca | 8/20/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
SCYX SCYNEXIS | 8/19/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
VXRT Vaxart | 8/15/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $6.00 | Low | |
VERU Veru | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $12.00 | High | |
NHWK NightHawk Biosciences | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $56.00 -> $56.00 | High | |
|
CLRB Cellectar Biosciences | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $60.00 -> $60.00 | High | |
ARCT Arcturus Therapeutics | 7/24/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
SCYX SCYNEXIS | 1/4/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | |
CLRB Cellectar Biosciences | 11/20/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
ARCT Arcturus Therapeutics | 9/27/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
NHWK NightHawk Biosciences | 8/1/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |
TNXP Tonix Pharmaceuticals | 7/27/2018 | Downgraded by | Brookline Capital Management | Analyst K. Raja | Buy -> Hold | | Low | |
TNXP Tonix Pharmaceuticals | 5/1/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | |